High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen

Hdl Handle:
http://hdl.handle.net/10144/619311
Title:
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen
Authors:
Ndjeka, N; Schnippel, K; Master, I; Meintjes, G; Maartens, G; Romero, R; Padanilam, X; Enwerem, M; Chotoo, S; Singh, N; Hughes, J; Variava, E; Ferreira, H; Te Riele, J; Ismail, N; Mohr, E; Bantubani, N; Conradie, F
Journal:
The European Respiratory Journal
Abstract:
Background: South African patients with rifampicin-resistant tuberculosis and resistance to fluoroquinolones and/or injectables (pre/XDR-TB) were granted access to bedaquiline through a Clinical Access Programme with strict inclusion and exclusion criteria.Methods: Pre/XDR-TB and XDR-TB patients were treated with 24 weeks bedaquiline within an optimised, individualised background regimen that could include levofloxacin, linezolid and clofazimine as needed.Results: 200 patients were enrolled: 87 (43.9%) with XDR-TB, 99 (49.3%) were female, median age 34 years (IQR 27, 42). 134 (67.0%) were living with HIV; median CD4+ 281 (IQR 130; 467) and all on antiretroviral therapy.16/200 patients (8.0%) did not complete 6 months of bedaquiline of which 8 were lost to follow up, 6 died, 1 stopped for side effects and 1 patient was diagnosed with drug-sensitive TB.146/200 (73.0%) patients had favourable outcomes: 139/200 were cured (69.5%) and 7 completed treatment (3.5%). 25 died (12.5%), were lost from treatment (10.0%), 9 had treatment failure (4.5%).22 adverse events were attributed to bedaquiline: including QTcF >500 ms (n=5), QTcF increase >50 ms from baseline (n=11), paroxysmal atrial flutter (n=1).Conclusion: Bedaquiline added to an optimised background regimen was associated with a high rate of successful treatment outcomes for this MDR-TB and XDR-TB cohort.
Publisher:
European Respiratory Society
Issue Date:
25-Oct-2018
URI:
http://hdl.handle.net/10144/619311
DOI:
10.1183/13993003.01528-2018
PubMed ID:
30361246
Submitted date:
2018-11-05
Language:
en
Description:
We regret that this article is behind a paywall.
ISSN:
1399-3003
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorNdjeka, Nen
dc.contributor.authorSchnippel, Ken
dc.contributor.authorMaster, Ien
dc.contributor.authorMeintjes, Gen
dc.contributor.authorMaartens, Gen
dc.contributor.authorRomero, Ren
dc.contributor.authorPadanilam, Xen
dc.contributor.authorEnwerem, Men
dc.contributor.authorChotoo, Sen
dc.contributor.authorSingh, Nen
dc.contributor.authorHughes, Jen
dc.contributor.authorVariava, Een
dc.contributor.authorFerreira, Hen
dc.contributor.authorTe Riele, Jen
dc.contributor.authorIsmail, Nen
dc.contributor.authorMohr, Een
dc.contributor.authorBantubani, Nen
dc.contributor.authorConradie, Fen
dc.date.accessioned2018-11-09T14:44:37Z-
dc.date.available2018-11-09T14:44:37Z-
dc.date.issued2018-10-25-
dc.date.submitted2018-11-05-
dc.identifier.citationHigh treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. 2018 Eur. Respir. J.en
dc.identifier.issn1399-3003-
dc.identifier.pmid30361246-
dc.identifier.doi10.1183/13993003.01528-2018-
dc.identifier.urihttp://hdl.handle.net/10144/619311-
dc.descriptionWe regret that this article is behind a paywall.en
dc.description.abstractBackground: South African patients with rifampicin-resistant tuberculosis and resistance to fluoroquinolones and/or injectables (pre/XDR-TB) were granted access to bedaquiline through a Clinical Access Programme with strict inclusion and exclusion criteria.Methods: Pre/XDR-TB and XDR-TB patients were treated with 24 weeks bedaquiline within an optimised, individualised background regimen that could include levofloxacin, linezolid and clofazimine as needed.Results: 200 patients were enrolled: 87 (43.9%) with XDR-TB, 99 (49.3%) were female, median age 34 years (IQR 27, 42). 134 (67.0%) were living with HIV; median CD4+ 281 (IQR 130; 467) and all on antiretroviral therapy.16/200 patients (8.0%) did not complete 6 months of bedaquiline of which 8 were lost to follow up, 6 died, 1 stopped for side effects and 1 patient was diagnosed with drug-sensitive TB.146/200 (73.0%) patients had favourable outcomes: 139/200 were cured (69.5%) and 7 completed treatment (3.5%). 25 died (12.5%), were lost from treatment (10.0%), 9 had treatment failure (4.5%).22 adverse events were attributed to bedaquiline: including QTcF >500 ms (n=5), QTcF increase >50 ms from baseline (n=11), paroxysmal atrial flutter (n=1).Conclusion: Bedaquiline added to an optimised background regimen was associated with a high rate of successful treatment outcomes for this MDR-TB and XDR-TB cohort.en
dc.language.isoenen
dc.publisherEuropean Respiratory Societyen
dc.titleHigh treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimenen
dc.identifier.journalThe European Respiratory Journalen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.